In The Press July 30, 2020

With Biggest Biotech SPAC Merger Yet, Cerevel’s Public Path Could Augur More Deals in Same Vein (BioCentury)

Cerevel’s path to NASDAQ via a SPAC is likely to presage similar deals for other life sciences companies. Biotechs and investors have increasingly made use this year of special purpose acquisition companies, which are blank-check shell companies that are set up to merge with private companies after themselves going public. The Goodwin life sciences team representing Cervel Therapeutics was led by Stuart Cable, Art McGivern, James Xu and John Mei, and the Goodwin SPAC team was led by Jocelyn Arel and Dan Espinoza. Read the BioCentury article here